ProCE Banner Activity

Clinical Case Study: Targeting BCMA With ADCs in MM

Slideset Download
Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.

Released: November 12, 2021

Expiration: November 11, 2022

Share

Faculty

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts